Actively Recruiting
Phase 1 Evaluation of LY4057996 Safety and Effects in Healthy Adults and Those with Type 1 and Type 2 Diabetes
Led by Eli Lilly and Company · Updated on 2026-09-29
124
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety, tolerability, pharmacokinetics, and pharmacodynamics of LY4057996 in healthy individuals and people with Type 1 or Type 2 Diabetes. This Phase 1 study aims to understand how well the drug is tolerated and what side effects may occur when administered through different methods. It includes both healthy participants and those with diabetes under various treatment conditions. Participants will receive LY4057996 either under the skin subcutaneously or into a vein in the arm intravenously. Some groups may receive placebo or other diabetes medications such as Degludec, Lispro, or basal insulin alongside LY4057996. The study is divided into parts lasting different durations Parts A1-A2 last about 11 weeks, A3-A5 about 4 weeks, Part B about 6 weeks, and Part C about 7 weeks, excluding screening. During the study, participants will undergo blood tests to measure how LY4057996 moves through and is eliminated by the body. Researchers will monitor for any serious or related side effects and track changes in fasting glucose and glucose infusion rates. The total study duration can be up to 47 weeks, including safety follow-up. Participants will have regular visits for assessments and monitoring throughout their assigned study part.
CONDITIONS
Brief Title
A Study of LY4057996 in Healthy Participants and Participants With Type 1 and Type 2 Diabetes
Research Team
T
Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
P
Physicians interested in becoming principal investigators please contact
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here